Login to Your Account



Celgene Hat Trick: Pomalyst Joins Multiple Myeloma Arsenal

By Marie Powers
Staff Writer

Monday, February 11, 2013
In October 2012, the FDA cancelled the Oncologic Drugs Advisory Committee meeting scheduled for Nov. 8, which was to include a review of the new drug application for pomalidomide, Celgene Corp.'s immunomodulatory drug (IMiD) candidate in multiple myeloma (MM).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription